肿瘤细胞对TRAIL耐受机制以及克服耐受性的研究进展  

The mechanisms of TRAIL resistance against tumor cells and researches for overcoming TRAIL resistance

作　　者：聂金梅[1] 徐雅君[1] 邢永梅[1] 李亨芬[1] 邹金[1] 白如玉[1] 刁勇[1] 

机构地区：[1]华侨大学分子药物学研究所

出　　处：《中国医药科学》2011年第15期43-45,共3页China Medicine And Pharmacy

基　　金：国家高技术研究发展计划("863计划";编号:2008AA02Z135);国家科技重大专项课题(编号:2009ZX09103-64)

摘　　要：TRAIL的全称是肿瘤坏死因子相关的凋亡诱导配体,也称为APO-2L,因为TRAIL与TNF和CD95/FasL具有同源性序列,因此确定TRAIL为TNF超家族成员之一,它属于Ⅱ型跨膜蛋白。到目前为止,研究重点关注于TRAIL诱导凋亡的作用机制和产生TRAIL耐受性的过程。化学疗法或放射疗法联合应用可使对TRAIL耐受的肿瘤恢复TRAIL敏感性。本综述关注TRAIL受体诱导的凋亡信号通路、肿瘤耐受TRAIL的机制以及可能克服耐受的方法。The full name of TRAIL is Tumor necrosis affected apoptosis-inducing ligand, which is also called Apo-2L,It is a member of the TNF superfamily as TRAIL was identified as a homologue of the Fas-ligand （Fas L）.TRAIL belonged to type Ⅱ transmembrane protein.So far,studies have focused on the mechanism of apoptosis induced by TRAIL and the processes involved in the development of TRAIL resistance.TRAIL-resistant tumours can be re-sensitized to TRAIL by combining TRAIL with chemotherapeutics or irradiation. This review focuses on the apoptotic signalling pathway induced by TRAIL receptors.The mechanisms of TRAIL resistance and the potential measures that can be taken to overcome them are also addressed.

关 键 词：TRAIL耐受性 死亡受体 拮抗受体 凋亡 肿瘤 联合治疗 

分 类 号：R730.5[医药卫生—肿瘤]